aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
-Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity-. -Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2 B and Facioscapulohumeral ...
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy
-63% of Patients Observed Increased Muscle Strength-. -Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population-. SAN DIEGO, April 24, 2017-- aTyr Pharma, Inc., a ...
- GlobeNewswire•15 days ago
SAN DIEGO, April 10, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the ...
LIFE : Summary for aTyr Pharma, Inc. - Yahoo Finance
aTyr Pharma, Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||3.15 x 900|
|Ask||3.20 x 5000|
|Day's Range||3.10 - 3.21|
|52 Week Range||2.10 - 4.45|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.31|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|